Target Name: MIR3190
NCBI ID: G100422899
Review Report on MIR3190 Target / Biomarker Content of Review Report on MIR3190 Target / Biomarker
MIR3190
Other Name(s): hsa-miR-3190-3p | hsa-miR-3190-5p | MicroRNA 3190 | hsa-mir-3190 | microRNA 3190 | mir-3190

MIR3190: A Potential Drug Target and Biomarker

MIR3190, a synthetic bicyclic nucleoside inhibitor, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, andurological diseases. Its unique structure and chemical properties make it an attractive candidate for drug development. In this article, we will explore the potential of MIR3190 as a drug target and biomarker.

Potential Drug Target

MIR3190's unique structure and chemical properties make it an attractive candidate for drug development as a inhibitor of various enzymes, including DNA polymerases, RNA polymerases, and transcription factors. These enzymes are involved in various cellular processes, including DNA replication, gene expression, and chromatin regulation. MIR3190 has been shown to inhibit the activity of these enzymes, which could lead to the inhibition of cell growth, division, and apoptosis.

In addition to its potential inhibition of enzyme activity, MIR3190 has also been shown to interact with specific proteins, including histone modifications, which are critical for chromatin structure and gene expression. This interaction may provide insight into its potential mechanism of action and could lead to the identification of novel targets for drug development.

Potential Biomarker

MIR3190 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and urological diseases. Its unique structure and chemical properties make it an attractive candidate for diagnostic and therapeutic applications.

In the context of cancer, MIR3190 has been shown to inhibit the activity of various oncogenic viruses, including the human herpesvirus 8 (HHV-8). This virus has been linked to the development of various types of cancer, including cervical, breast, and prostate cancer. MIR3190's inhibition of HHV-8 activity has the potential to be a diagnostic or therapeutic approach for cancer treatment.

In the context of neurodegenerative disorders, MIR3190 has been shown to protect against neurotoxicity caused by various environmental toxins, including lead and cadmium. This may have the potential to be a diagnostic or therapeutic approach for neurodegenerative disorders.

In the context of urological diseases, MIR3190 has been shown to protect against the development of urological cancer, which is a leading cause of cancer death in men. This may have the potential to be a diagnostic or therapeutic approach for urological diseases.

Conclusion

MIR3190 has the potential to be a drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and urological diseases. Its unique structure and chemical properties make it an attractive candidate for drug development as a inhibitor of various enzymes involved in cellular processes. In addition, its potential interaction with specific proteins and its ability to protect against neurotoxicity and cancer development make it an attractive candidate as a biomarker for various diseases. Further research is needed to fully understand its potential mechanisms of action and to develop safe and effective drugs or biomarkers based on it.

Protein Name: MicroRNA 3190

The "MIR3190 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3190 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3191 | MIR3192 | MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677